Skip to main content

Pharmacokinetics and Pharmacodynamics of Colistin

Abstract

The increasing prevalence of multidrug-resistant Gram-negative bacteria worldwide has resulted in colistin, administered as its inactive prodrug colistin methanesulfonate (CMS), being increasingly used as a last-line therapy to treat infections caused by these pathogens. Developed well before contemporary drug development procedures, substantial improvements in the understanding of its chemistry, pharmacokinetics (PK), pharmacodynamics (PD) and PK/PD relationships have occurred over the last decade which have enabled substantial progress towards optimising its clinical use in different patient populations. This has resulted in the first scientifically based dosing algorithm for various categories of critically ill patients receiving CMS to generate a desired target steady-state plasma concentration of formed colistin. It has become clear that monotherapy with CMS is unlikely to generate plasma colistin concentrations that are reliably efficacious. With nephrotoxicity preventing simply increasing the dose of CMS, combination therapy may be required in order to maximise efficacy and minimise the emergence of resistance.

Keywords

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • al-Khayyat AA, Aronson AL (1973) Pharmacologic and toxicologic studies with the polymyxins. II. Comparative pharmnacologic studies of the sulfate and methanesulfonate salts of polymyxin B and colistin in dogs. Chemotherapy 19:82–97

    CAS  PubMed  Google Scholar 

  • Al-Sweih NA, Al-Hubail MA, Rotimi VO (2011) Emergence of tigecycline and colistin resistance in acinetobacter species isolated from patients in Kuwait hospitals. J Chemother 23:13–16

    CAS  PubMed  Google Scholar 

  • Andrews JM, Howe RA (2011) BSAC standardized disc susceptibility testing method (version 10). J Antimicrob Chemother 66:2726–2757

    CAS  PubMed  Google Scholar 

  • Antoniadou A, Kontopidou F, Poulakou G et al (2007) Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J Antimicrob Chemother 59:786–790

    CAS  PubMed  Google Scholar 

  • Aoki N, Tateda K, Kikuchi Y et al (2009) Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 63:534–542

    CAS  PubMed  Google Scholar 

  • Barnett M, Bushby SR, Wilkinson S (1964) Sodium sulphomethyl derivatives of polymyxins. Br J Pharmacol 23:552–574

    CAS  Google Scholar 

  • Beceiro A, Llobet E, Aranda J et al (2011) Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system. Antimicrob Agents Chemother 55:3370–3379

    CAS  PubMed Central  PubMed  Google Scholar 

  • Bergen PJ, Li J, Rayner CR et al (2006) Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 50:1953–1958

    CAS  PubMed Central  PubMed  Google Scholar 

  • Bergen PJ, Li J, Nation RL et al (2008) Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J Antimicrob Chemother 61:636–642

    CAS  PubMed  Google Scholar 

  • Bergen PJ, Bulitta JB, Forrest A et al (2010) Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model. Antimicrob Agents Chemother 54:3783–3789

    CAS  PubMed Central  PubMed  Google Scholar 

  • Bergen PJ, Forrest A, Bulitta JB et al (2011a) Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant pseudomonas aeruginosa at multiple inocula. Antimicrob Agents Chemother 55:5134–5142

    CAS  PubMed Central  PubMed  Google Scholar 

  • Bergen PJ, Tsuji BT, Bulitta JB et al (2011b) Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 55:5685–5695

    CAS  PubMed Central  PubMed  Google Scholar 

  • Betrosian AP, Frantzeskaki F, Xanthaki A et al (2008) Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect 56:432–436

    PubMed  Google Scholar 

  • Beveridge EG, Martin AJ (1967) Sodium sulphomethyl derivatives of polymyxins. Br J Pharmacol Chemother 29:125–135

    CAS  PubMed Central  PubMed  Google Scholar 

  • Bogdanovich T, Adams-Haduch JM, Tian GB et al (2011) Colistin-resistant, Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae belonging to the international epidemic clone ST258. Clin Infect Dis 53:373–376

    PubMed  Google Scholar 

  • Boucher HW, Talbot GH, Bradley JS et al (2009) Bad bugs, no drugs: no ESKAPE! an update from the infectious diseases society of America. Clin Infect Dis 48:1–12

    PubMed  Google Scholar 

  • Bratu S, Landman D, Haag R et al (2005) Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 165:1430–1435

    CAS  PubMed  Google Scholar 

  • Breazeale SD, Ribeiro AA, McClerren AL et al (2005) A formyltransferase required for polymyxin resistance in Escherichia coli and the modification of lipid A with 4-amino-4-deoxy-L-arabinose. Identification and function oF UDP-4-deoxy-4-formamido-L-arabinose. J Biol Chem 280:14154–14167

    CAS  PubMed  Google Scholar 

  • Brogden KA (2005) Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 3:238–250

    CAS  PubMed  Google Scholar 

  • Bulitta JB, Yang JC, Yohonn L et al (2010) Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model. Antimicrob Agents Chemother 54:2051–2062

    CAS  PubMed Central  PubMed  Google Scholar 

  • Cernohorska L, Slavikova P (2010) Antibiotic resistance and biofilm formation in Pseudomonas aeruginosa strains isolated from patients with urinary tract infections. Epidemiol Mikrobiol Imunol 59:154–157

    Google Scholar 

  • Clinical and Laboratory Standards Institute (CLSI) (2012) Performance standards for antimicrobial susceptibility testing: twentieth informational supplement (M100-S20). CLSI, Wayne, PA

    Google Scholar 

  • Coly-Mycin M Parenteral [package insert] (2005). Monarch Pharmaceuticals, Bristol, TN

    Google Scholar 

  • Comite de l’ Antibiogramme de la Societe Francaise de Microbiologie (SFM) (2005). Recommandations du CSFM, Communique: edition de Janvier 2005. http://www.sfm.asso.fr/. Accessed 31 July 2012

  • Couet W, Gregoire N, Gobin P et al (2011) Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin Pharmacol Ther 89:875–879

    CAS  PubMed  Google Scholar 

  • Craig WA, Kunin CM (1973) Dynamics of binding and release of the polymyxin antibiotics by tissues. J Pharmacol Exp Ther 184:757–765

    CAS  PubMed  Google Scholar 

  • David MD, Gill MJ (2008) Potential for underdosing and emergence of resistance in Acinetobacter baumannii during treatment with colistin. J Antimicrob Chemother 61:962–964

    CAS  PubMed  Google Scholar 

  • Decolin D, Leroy P, Nicolas A et al (1997) Hyphenated liquid chromatographic method for the determination of colistin residues in bovine tissues. J Chromatogr Sci 35:557–564

    CAS  PubMed  Google Scholar 

  • Deris ZZ, Yu HH, Davis K et al (2012) Colistin and doripenem combination is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro PK/PD model. Antimicrob Agents Chemother 56(10):5103–5112

    CAS  PubMed Central  PubMed  Google Scholar 

  • DeRyke CA, Crawford AJ, Uddin N et al (2010) Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 54:4503–4505

    CAS  PubMed Central  PubMed  Google Scholar 

  • Dotsikas Y, Markopoulou CK, Koundourellis JE et al (2011) Validation of a novel LC-MS/MS method for the quantitation of colistin A and B in human plasma. J Sep Sci 34:37–45

    CAS  PubMed  Google Scholar 

  • Dudhani RV, Li J, Nation RL (2009). Plasma binding of colistin involves multiple proteins and is concentration dependent: potential clinical implications (abstract A1-576, p41). In: Abstracts of the 49th annual interscience conference on antimicrobial agents and chemotherapy (ICAAC), American Society for Microbiology San Francisco, CA, 12–15 Sept 2009

    Google Scholar 

  • Dudhani RV, Nation RL, Li J (2010a) Evaluating the stability of colistin and colistin methanesulphonate in human plasma under different conditions of storage. J Antimicrob Chemother 65:1412–1415

    CAS  PubMed  Google Scholar 

  • Dudhani RV, Turnidge JD, Coulthard K et al (2010b) Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother 54:1117–1124

    CAS  PubMed Central  PubMed  Google Scholar 

  • Dudhani RV, Turnidge JD, Nation RL et al (2010c) fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother 65:1984–1990

    CAS  PubMed  Google Scholar 

  • Eickhoff TC, Finland M (1965) Polymyxin B and colistin: in vitro activity against Pseudomonas aeruginosa. Am J Med Sci 249:172–174

    CAS  PubMed  Google Scholar 

  • European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2012). Breakpoint tables for interpretation of MICs and zone diameters (Version 2.0, January 1, 2012). http://www.eucast.org/clinical_breakpoints/. Accessed 31 July 2012

  • Falagas ME, Kasiakou SK (2005) Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 40:1333–1341

    CAS  PubMed  Google Scholar 

  • Falagas ME, Kasiakou SK (2006) Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 10:R27

    PubMed  Google Scholar 

  • Falagas ME, Rizos M, Bliziotis IA et al (2005) Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis 5:1

    PubMed Central  PubMed  Google Scholar 

  • Fernandez L, Gooderham WJ, Bains M et al (2010) Adaptive resistance to the “last hope” antibiotics polymyxin B and colistin in Pseudomonas aeruginosa is mediated by the novel two-component regulatory system ParR-ParS. Antimicrob Agents Chemother 54:3372–3382

    CAS  PubMed Central  PubMed  Google Scholar 

  • Finland M, Garner C, Wilcox C et al (1976a) Susceptibility of beta-hemolytic streptococci to 65 antibacterial agents. Antimicrob Agents Chemother 9:11–19

    CAS  PubMed Central  PubMed  Google Scholar 

  • Finland M, Garner C, Wilcox C et al (1976b) Susceptibility of pneumococci and Haemophilus influenzae to antibacterial agents. Antimicrob Agents Chemother 9:274–287

    CAS  PubMed Central  PubMed  Google Scholar 

  • Gales AC, Jones RN, Sader HS (2011) Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006–09). J Antimicrob Chemother 66:2070–2074

    CAS  PubMed  Google Scholar 

  • Garonzik SM, Li J, Thamlikitkul V et al (2011) Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55:3284–3294

    CAS  PubMed Central  PubMed  Google Scholar 

  • Gobin P, Lemaitre F, Marchand S et al (2010) Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother 54:1941–1948

    CAS  PubMed Central  PubMed  Google Scholar 

  • Gunderson BW, Ibrahim KH, Hovde LB et al (2003) Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 47:905–909

    PubMed Central  PubMed  Google Scholar 

  • Hale JD, Hancock RE (2007) Alternative mechanisms of action of cationic antimicrobial peptides on bacteria. Expert Rev Anti Infect Ther 5:951–959

    CAS  PubMed  Google Scholar 

  • Hancock RE, Chapple DS (1999) Peptide antibiotics. Antimicrob Agents Chemother 43:1317–1323

    CAS  PubMed Central  PubMed  Google Scholar 

  • Hancock RE, Rozek A (2002) Role of membranes in the activities of antimicrobial cationic peptides. FEMS Microbiol Lett 206:143–149

    CAS  PubMed  Google Scholar 

  • Hancock RE, Falla T, Brown M (1995) Cationic bactericidal peptides. Adv Microb Physiol 37:135–175

    CAS  PubMed  Google Scholar 

  • Hartzell JD, Neff R, Ake J et al (2009) Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 48:1724–1728

    CAS  PubMed  Google Scholar 

  • Hawley JS, Murray CK, Jorgensen JH (2008) Colistin heteroresistance in acinetobacter and its association with previous colistin therapy. Antimicrob Agents Chemother 52:351–352

    CAS  PubMed Central  PubMed  Google Scholar 

  • Hawser SP (2010) Susceptibility of Klebsiella pneumoniae clinical isolates from 2007 to 2009 to colistin and comparator antibiotics. Int J Antimicrob Agents 36:383–384

    CAS  PubMed  Google Scholar 

  • Helander IM, Kato Y, Kilpelainen I et al (1996) Characterization of lipopolysaccharides of polymyxin-resistant and polymyxin-sensitive Klebsiella pneumoniae O3. Eur J Biochem 237:272–278

    CAS  PubMed  Google Scholar 

  • Hengzhuang W, Wu H, Ciofu O et al (2012) In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection. Antimicrob Agents Chemother 56:2683–2690

    PubMed Central  PubMed  Google Scholar 

  • Hoeprich PD (1970) The polymyxins. Med Clin North Am 54:1257–1265

    CAS  PubMed  Google Scholar 

  • Imberti R, Cusato M, Villani P et al (2010) Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest 138:1333–1339

    CAS  PubMed  Google Scholar 

  • Infectious Disease Society of America (IDSA) (2010) The 10 x ’20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 50:1081–1083

    Google Scholar 

  • Institute for Safe Medication Practices (ISMP) (2011) National Alert Network: Warning! Dosing confusion with colistmethate for injection. http://www.ashp.org/DocLibrary/Policy/PatientSafety/NANAlert-Colistimethatesodium.aspx. Accessed 1 Aug 2012

  • Jansson B, Karvanen M, Cars O et al (2009) Quantitative analysis of colistin A and colistin B in plasma and culture medium using a simple precipitation step followed by LC/MS/MS. J Pharm Biomed Anal 49:760–767

    CAS  PubMed  Google Scholar 

  • Johansen HK, Moskowitz SM, Ciofu O et al (2008) Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients. J Cyst Fibros 7:391–397

    PubMed  Google Scholar 

  • Ketthireddy S, Lee DG, Murakami Y et al (2007) In vivo pharmacodynamics of colistin against Pseudomonas aeruginosa in thighs of neutropenic mice (abstract A-4, p1). In: Abstracts of the 47th interscience conference on antimicrobial agents and chemotherapy (ICAAC), American Society for Microbiology, Chicago, IL, 17–20 Sept 2007

    Google Scholar 

  • Ko KS, Suh JY, Kwon KT et al (2007) High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother 60:1163–1167

    CAS  PubMed  Google Scholar 

  • Ko H, Jeon M, Choo E et al (2011) Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin. Nephron Clin Pract 117:c284–c288

    CAS  PubMed  Google Scholar 

  • Kontopoulou K, Protonotariou E, Vasilakos K et al (2010) Hospital outbreak caused by Klebsiella pneumoniae producing KPC-2 beta-lactamase resistant to colistin. J Hosp Infect 76:70–73

    CAS  PubMed  Google Scholar 

  • Koyama Y, Kurosasa A, Tsuchiya A et al (1950) A new antibiotic ‘colistin’ produced by spore-forming soil bacteria. J Antibiot 3:457–458

    Google Scholar 

  • Kumar A, Roberts D, Wood KE et al (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34:1589–1596

    PubMed  Google Scholar 

  • Kunin CM, Bugg A (1971) Binding of polymyxin antibiotics to tissues: the major determinant of distribution and persistence in the body. J Infect Dis 124:394–400

    CAS  PubMed  Google Scholar 

  • Kwon JA, Lee JE, Huh W et al (2010) Predictors of acute kidney injury associated with intravenous colistin treatment. Int J Antimicrob Agents 35:473–477

    CAS  PubMed  Google Scholar 

  • Landman D, Georgescu C, Martin DA et al (2008) Polymyxins revisited. Clin Microbiol Rev 21:449–465

    CAS  PubMed Central  PubMed  Google Scholar 

  • Lee JY, Song JH, Ko KS (2011) Identification of nonclonal Pseudomonas aeruginosa isolates with reduced colistin susceptibility in Korea. Microb Drug Resist 17:299–304

    CAS  PubMed  Google Scholar 

  • Leroy P, Decolin D, Nicolas S et al (1989) Residue determination of two co-administered antibacterial agents–cephalexin and colistin–in calf tissues using high-performance liquid chromatography and microbiological methods. J Pharm Biomed Anal 7:1837–1846

    CAS  PubMed  Google Scholar 

  • Lewis JR, Lewis SA (2004) Colistin interactions with the mammalian urothelium. Am J Physiol Cell Physiol 286:C913–C922

    CAS  PubMed  Google Scholar 

  • Lewis LA, Choudhury B, Balthazar JT et al (2009) Phosphoethanolamine substitution of lipid A and resistance of Neisseria gonorrhoeae to cationic antimicrobial peptides and complement-mediated killing by normal human serum. Infect Immun 77:1112–1120

    CAS  PubMed Central  PubMed  Google Scholar 

  • Li J, Milne RW, Nation RL et al (2001a) A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 761:167–175

    CAS  PubMed  Google Scholar 

  • Li J, Turnidge J, Milne R et al (2001b) In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 45:781–785

    CAS  PubMed Central  PubMed  Google Scholar 

  • Li J, Milne RW, Nation RL et al (2002) Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob Agents Chemother 46:3304–3307

    CAS  PubMed Central  PubMed  Google Scholar 

  • Li J, Coulthard K, Milne R et al (2003a) Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother 52:987–992

    CAS  PubMed  Google Scholar 

  • Li J, Milne RW, Nation RL et al (2003b) Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob Agents Chemother 47:1364–1370

    CAS  PubMed Central  PubMed  Google Scholar 

  • Li J, Milne RW, Nation RL et al (2003c) Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob Agents Chemother 47:1766–1770

    CAS  PubMed Central  PubMed  Google Scholar 

  • Li J, Milne RW, Nation RL et al (2004) Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother 53:837–840

    CAS  PubMed  Google Scholar 

  • Li J, Nation RL, Milne RW et al (2005a) Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 25:11–25

    PubMed  Google Scholar 

  • Li J, Rayner CR, Nation RL et al (2005b) Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 49:4814–4815

    CAS  PubMed Central  PubMed  Google Scholar 

  • Li J, Nation RL, Turnidge JD (2006a) Defining the dosage units for colistin methanesulfonate: urgent need for international harmonization. Antimicrob Agents Chemother 50(12):4231, author reply 4231–4232

    CAS  PubMed Central  PubMed  Google Scholar 

  • Li J, Nation RL, Turnidge JD et al (2006b) Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 6:589–601

    CAS  PubMed  Google Scholar 

  • Li J, Rayner CR, Nation RL et al (2006c) Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 50:2946–2950

    CAS  PubMed Central  PubMed  Google Scholar 

  • Lim LM, Ly N, Anderson D et al (2010) Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 30:1279–1291

    CAS  PubMed  Google Scholar 

  • Lin KH, Chuang YC, Lee SH et al (2010) In vitro synergistic antimicrobial effect of imipenem and colistin against an isolate of multidrug-resistant Enterobacter cloacae. J Microbiol Immunol Infect 43:317–322

    PubMed  Google Scholar 

  • Livermore DM (2004) The need for new antibiotics. Clin Microbiol Infect 10(Suppl 4):1–9

    PubMed  Google Scholar 

  • Llobet E, Tomas JM, Bengoechea JA (2008) Capsule polysaccharide is a bacterial decoy for antimicrobial peptides. Microbiology 154:3877–3886

    CAS  PubMed  Google Scholar 

  • Luna CM, Aruj P, Niederman MS et al (2006) Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur Respir J 27:158–164

    CAS  PubMed  Google Scholar 

  • Ma Z, Wang J, Nation RL et al (2009) Renal disposition of colistin in the isolated perfused rat kidney. Antimicrob Agents Chemother 53:2857–2864

    CAS  PubMed Central  PubMed  Google Scholar 

  • Mackay DN, Kaye D (1964) Serum concentrations of colistin in patients with normal and impaired renal function. N Engl J Med 270:394–397

    CAS  PubMed  Google Scholar 

  • Marchaim D, Chopra T, Pogue JM et al (2011) Outbreak of colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan. Antimicrob Agents Chemother 55:593–599

    CAS  PubMed Central  PubMed  Google Scholar 

  • Marchand S, Frat JP, Petitpas F et al (2010a) Removal of colistin during intermittent haemodialysis in two critically ill patients. J Antimicrob Chemother 65:1836–1837

    CAS  PubMed  Google Scholar 

  • Marchand S, Lamarche I, Gobin P et al (2010b) Dose-ranging pharmacokinetics of colistin methanesulphonate (CMS) and colistin in rats following single intravenous CMS doses. J Antimicrob Chemother 65:1753–1758

    CAS  PubMed  Google Scholar 

  • Markou N, Markantonis SL, Dimitrakis E et al (2008) Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther 30:143–151

    CAS  PubMed  Google Scholar 

  • Meletis G, Tzampaz E, Sianou E et al (2011) Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother 66:946–947

    CAS  PubMed  Google Scholar 

  • Mezzatesta ML, Gona F, Caio C et al (2011) Outbreak of KPC-3-producing, and colistin-resistant, Klebsiella pneumoniae infections in two Sicilian hospitals. Clin Microbiol Infect 17:1444–1447

    CAS  PubMed  Google Scholar 

  • Michalopoulos AS, Karatza DC (2010) Multidrug-resistant Gram-negative infections: the use of colistin. Expert Rev Anti Infect Ther 8:1009–1017

    CAS  PubMed  Google Scholar 

  • Moffatt JH, Harper M, Harrison P et al (2010) Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother 54:4971–4977

    CAS  PubMed Central  PubMed  Google Scholar 

  • Mohamed AF, Karaiskos I, Plachouras D et al (2012) Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother 56:4241–4249

    CAS  PubMed Central  PubMed  Google Scholar 

  • Molina J, Cordero E, Pachon J (2009) New information about the polymyxin/colistin class of antibiotics. Expert Opin Pharmacother 10:2811–2828

    CAS  PubMed  Google Scholar 

  • Morita K, Yamaji A (1995) Changes in the serum protein binding of vancomycin in patients with methicillin-resistant Staphylococcus aureus infection: the role of serum alpha 1-acid glycoprotein levels. Ther Drug Monit 17:107–112

    CAS  PubMed  Google Scholar 

  • Morrison AJ Jr, Wenzel RP (1984) Epidemiology of infections due to Pseudomonas aeruginosa. Rev Infect Dis 6(Suppl 3):S627–S642

    PubMed  Google Scholar 

  • Moskowitz SM, Ernst RK, Miller SI (2004) PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A. J Bacteriol 186:575–579

    CAS  PubMed Central  PubMed  Google Scholar 

  • Nation RL, Li J (2009) Colistin in the 21st century. Curr Opin Infect Dis 22:535–543

    CAS  PubMed Central  PubMed  Google Scholar 

  • Opal SM, Calandra T (2009) Antibiotic usage and resistance: gaining or losing ground on infections in critically ill patients? JAMA 302:2367–2368

    CAS  PubMed  Google Scholar 

  • Orwa JA, Van Gerven A, Roets E et al (2000) Development and validation of a liquid chromatography method for analysis of colistin sulphate. Chromatographia 51:433–436

    CAS  Google Scholar 

  • Orwa JA, Govaerts C, Busson R et al (2001) Isolation and structural characterization of colistin components. J Antibiot (Tokyo) 54:595–599

    CAS  Google Scholar 

  • Owen RJ, Li J, Nation RL et al (2007) In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 59:473–477

    CAS  PubMed  Google Scholar 

  • Ozbek B, Senturk A (2010) Postantibiotic effects of tigecycline, colistin sulfate, and levofloxacin alone or tigecycline-colistin sulfate and tigecycline-levofloxacin combinations against Acinetobacter baumannii. Chemotherapy 56:466–471

    PubMed  Google Scholar 

  • Ozyilmaz E, Ebinc FA, Derici U et al (2011) Could nephrotoxicity due to colistin be ameliorated with the use of N-acetylcysteine? Intensive Care Med 37:141–146

    CAS  PubMed  Google Scholar 

  • Pintado V, San Miguel LG, Grill F et al (2008) Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria. J Infect 56:185–190

    PubMed  Google Scholar 

  • Plachouras D, Karvanen M, Friberg LE et al (2009) Population pharmacokinetic analysis of colistin methanesulphonate and colistin after intravenous administration in critically ill patients with gram-negative bacterial infections. Antimicrob Agents Chemother 53:3430–3436

    CAS  PubMed Central  PubMed  Google Scholar 

  • Poudyal A, Howden BP, Bell JM et al (2008) In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J Antimicrob Chemother 62:1311–1318

    CAS  PubMed  Google Scholar 

  • Queenan AM, Pillar CM, Deane J et al (2012) Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010. Diagn Microbiol Infect Dis 73:267–270

    CAS  PubMed  Google Scholar 

  • Rosenvinge A, Pressler T, Hoiby N (2005) Colistin intravenously is a safe and effective treatment of multidrug-resistant microorganisms in cystic fibrosis. J Cyst Fibros 4:S32

    Google Scholar 

  • Sader HS, Farrell DJ, Jones RN (2011) Susceptibility of Klebsiella spp. to colistin and polymyxin B: results from the SENTRY Antimicrobial Surveillance Program (2006–2009). Int J Antimicrob Agents 37:174–175

    CAS  PubMed  Google Scholar 

  • Schwartz BS, Warren MR, Barkley FA et al (1959) Microbiological and pharmacological studies of colistin sulfate and sodium colistinmethanesulfonate. Antibiot Annu 7:41–60

    PubMed  Google Scholar 

  • Spellberg B, Blaser M, Guidos RJ et al (2011) Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis 52(Suppl 5):S397–S428

    PubMed  Google Scholar 

  • Suh JY, Son JS, Chung DR et al (2010) Nonclonal emergence of colistin-resistant Klebsiella pneumoniae isolates from blood samples in South Korea. Antimicrob Agents Chemother 54:560–562

    CAS  PubMed Central  PubMed  Google Scholar 

  • Tan TY, Ng SY (2006) The in-vitro activity of colistin in gram-negative bacteria. Singapore Med J 47:621–624

    CAS  PubMed  Google Scholar 

  • Tan CH, Li J, Nation RL (2007) Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 51:3413–3415

    CAS  PubMed Central  PubMed  Google Scholar 

  • Toth A, Damjanova I, Puskas E et al (2010) Emergence of a colistin-resistant KPC-2-producing Klebsiella pneumoniae ST258 clone in Hungary. Eur J Clin Microbiol Infect Dis 29:765–769

    CAS  PubMed  Google Scholar 

  • Trotman RL, Williamson JC, Shoemaker DM et al (2005) Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 41:1159–1166

    CAS  PubMed  Google Scholar 

  • Voulgari F, Cummins P, Gardecki TI et al (1982) Serum levels of acute phase and cardiac proteins after myocardial infarction, surgery, and infection. Br Heart J 48:352–356

    CAS  PubMed Central  PubMed  Google Scholar 

  • Walkty A, DeCorby M, Nichol K et al (2009) In vitro activity of colistin (polymyxin E) against 3,480 isolates of gram-negative bacilli obtained from patients in Canadian hospitals in the CANWARD study, 2007–2008. Antimicrob Agents Chemother 53:4924–4926

    CAS  PubMed Central  PubMed  Google Scholar 

  • Wallace SJ, Li J, Nation RL et al (2008a) Subacute toxicity of colistin methanesulfonate in rats: comparison of various intravenous dosage regimens. Antimicrob Agents Chemother 52:1159–1161

    CAS  PubMed Central  PubMed  Google Scholar 

  • Wallace SJ, Li J, Rayner CR et al (2008b) Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients. Antimicrob Agents Chemother 52:3047–3051

    CAS  PubMed Central  PubMed  Google Scholar 

  • Wallace SJ, Li J, Nation RL et al (2010) Self-assembly behavior of colistin and its prodrug colistin methanesulfonate: implications for solution stability and solubilization. J Phys Chem B 114:4836–4840

    CAS  PubMed Central  PubMed  Google Scholar 

  • Winfield MD, Latifi T, Groisman EA (2005) Transcriptional regulation of the 4-amino-4-deoxy-L-arabinose biosynthetic genes in Yersinia pestis. J Biol Chem 280:14765–14772

    CAS  PubMed  Google Scholar 

  • Yau W, Owen RJ, Poudyal A et al (2009) Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme. J Infect 58:138–144

    PubMed  Google Scholar 

  • Yousef JM, Chen G, Hill PA et al (2011) Melatonin attenuates colistin-induced nephrotoxicity in rats. Antimicrob Agents Chemother 55:4044–4049

    CAS  PubMed Central  PubMed  Google Scholar 

  • Yousef JM, Chen G, Hill PA et al (2012) Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics. J Antimicrob Chemother 67:452–459

    CAS  PubMed  Google Scholar 

  • Zavascki AP, Goldani LZ, Cao G et al (2008) Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis 47:1298–1304

    CAS  PubMed  Google Scholar 

  • Ziv G, Sulman FG (1972) Binding of antibiotics to bovine and ovine serum. Antimicrob Agents Chemother 2:206–213

    CAS  PubMed Central  PubMed  Google Scholar 

  • Ziv G, Nouws JF, van Ginneken CA (1982) The pharmacokinetics and tissue levels of polymyxin B, colistin and gentamicin in calves. J Vet Pharmacol Ther 5:45–58

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

RLN and JL are supported by Award Number R01AI079330 and Award Number R01AI070896 from the National Institute of Allergy and Infectious Diseases. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health. JL is an Australian National Health and Medical Research Council Senior Research Fellow.

The authors do not have any financial, commercial or proprietary interest in any drug, device or equipment mentioned in this article.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Roger L. Nation Ph.D. .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Nation, R.L., Bergen, P.J., Li, J. (2014). Pharmacokinetics and Pharmacodynamics of Colistin. In: Vinks, A., Derendorf, H., Mouton, J. (eds) Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics. Springer, New York, NY. https://doi.org/10.1007/978-0-387-75613-4_14

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-75613-4_14

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-75612-7

  • Online ISBN: 978-0-387-75613-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics